Cydectin

(Moxidectin)

ApprovedSmall molecule

MMedicines Development for Global Health

Moxidectin is used to treat and prevent parasitic worm infections in livestock, horses, and pets by killing internal and external parasites like worms and mites.[2] Cydectin is currently approved and in use across 4 indications[4].[1]

Cydectin is one of 12 small molecule programs targeting Onchocerciasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

OnchocerciasisActive, not recruiting

Ocular OnchocerciasisActive, not recruiting

HelminthiasisActive, not recruiting

StrongyloidiasisApproved

OnchocerciasisApproved

Active, not recruiting

Ocular OnchocerciasisApproved

Active, not recruiting

HelminthiasisApproved

Active, not recruiting

StrongyloidiasisApproved

Approved

Competition

Competitive Landscape

17 competitors in Onchocerciasis

#DrugCompanyPhaseTrials

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

7 2

Rifadin

Sanofi

Approved

—3

Cydectin

MMedicines Development for Global Health

Approved

3 4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Albendazole.

2 6

Emodepside

JJennifer Keiser

Phase 2

1 7

Hetrazan

WWyeth-Lederle Vaccines

Preclinical

1 8

Albenza

IImpax Laboratories, LLC

Preclinical

1 9

Bi-Annual CDTI

UUniversiteit Antwerpen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Post-ApprovalRecruiting

Onchocerciasis

NCT07145736

Clinical

Trials by Indication[1]

Efficacy and Safety6 trials

Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

Completed·JJennifer Keiser·Phase 2/3·NCT04700423·536 enrolled

Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura

Completed·SSwiss Tropical & Public Health Institute·Phase 2·NCT03501251·286 enrolled

Efficacy and Safety of MOX/ALB Co-administration

Completed·JJennifer Keiser·Phase 3·NCT04726969·255 enrolled

Show 3 more trials

Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC

Completed·JJennifer Keiser·Phase 3·NCT06188715·224 enrolled

Efficacy and Safety Study of Moxidectin in Adults With Scabies

Completed·MMedicines Development for Global Health·Phase 2·NCT05875441·200 enrolled

Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Completed·JJennifer Keiser·Phase 3·NCT04848688·332 enrolled

Onchocerciasis3 trials

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases

Recruiting·KKirby Institute·Phase 4·NCT07145736·52,000 enrolled

Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

Active, not recruiting·MMedicines Development for Global Health·Phase 3·NCT03876262·323 enrolled

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

Completed·MMedicines Development for Global Health·Phase 3·NCT04311671·12,979 enrolled

Infection2 trials

Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

Completed·MMedicines Development for Global Health·Phase 3·NCT00790998·1,497 enrolled

Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection

Completed·MMedicines Development for Global Health·Phase 2·NCT00300768·172 enrolled

Treatment2 trials

A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

Completed·MMedicines Development for Global Health·Phase 1·NCT03962062·36 enrolled

Dose-finding Study of Moxidectin for Treatment of Scabies

Completed·MMedicines Development for Global Health·Phase 2·NCT03905265·22 enrolled

Safety and Efficacy2 trials

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

Completed·CCenter for Research on Filariasis and Other Tropical Diseases, Cameroon·Phase 2·NCT04049851·72 enrolled

Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

Completed·EEye Research Foundation, Inc.·Phase 4·NCT06795165·24 enrolled

7 more indications

Pediatric1 trial

Pediatric Pharmacokinetics And Safety Study Of Moxidectin

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT01035619

Midazolam1 trial

Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00856362·38 enrolled

Cardiac1 trial

Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

Completed·MMedicines Development for Global Health·Phase 1·NCT03012828·60 enrolled

Single Dose1 trial

Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin

Completed· Pfizer logo

Pfizer·Phase 1·NCT00736697·54 enrolled

Breastfeeding1 trial

Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women

Completed· Pfizer logo

Pfizer·Phase 1·NCT00751764·12 enrolled

Efficacy1 trial

Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Completed·JJennifer Keiser·Phase 2/3·NCT04056325·617 enrolled

Unspecified1 trial

Moxidectin for LF, Cote d'Ivoire (DOLF)

Completed·WWashington University School of Medicine·Phase 3·NCT04410406·164 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 13, 2018

MOXIDECTIN

NDA NDA210867

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Moxidectin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cydectin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Moxidectin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Moxidectin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA210867). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Medicines Development for Global Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: MMedicines Development for Global Health

Cydectin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Efficacy and Safety6 trials

Onchocerciasis3 trials

Infection2 trials

Treatment2 trials

Safety and Efficacy2 trials

Pediatric1 trial

Midazolam1 trial

Cardiac1 trial

Single Dose1 trial

Breastfeeding1 trial

Efficacy1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News